Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for
the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis …

G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly
due to their substantial involvement in human pathophysiology and their pharmacological …

OBJECTIVE This trial compared the efficacy and safety of the first oral glucagon-like peptide
1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with …

Abstract Pasien Diabetes Mellitus dapat hidup normal dengan mengendalikan faktor risiko.
Tujuan penelitian ini untuk mengetahui faktor risiko Diabetes Mellitus tipe dua. Desain studi …

Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …

As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …